We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
Drugs of Today 2010 December
After metformin, with insulin in patients with severe hyperglycemia, current recommendations on treatment for type 2 diabetes suggest several pharmacotherapies, including sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors and others. Among them, recent data emphasize the effectiveness at a lower risk for hypoglycemia of dipeptidyl peptidase-4 inhibitors compared to other drug groups. One particular drug from this group, sitagliptin offers sound effectiveness, safety and tolerability resulting in good glycemic control at a very low risk for hypoglycemia. This review explores available evidence on the optimal treatment for type 2 diabetes regarding glycemic control with minimal risk for hypoglycemia based on evidence from clinical trials and meta-analyses within the context of the current treatment recommendations by the Spanish Society of Diabetes.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app